唑来磷酸对阿那曲唑致乳腺癌患者骨量减少的抑制作用  

Inhibitory effect of zoledronic acid on anastrozole-induced osteopenia in breast cancer patients

作　　者：王汉晋[1] 胡云[1] 周萍[1] 朱春花[1] 黄敏[1] 

机构地区：[1]南京医科大学附属南京医院普通外科,江苏省210006

出　　处：《江苏医药》2013年第23期2845-2847,共3页Jiangsu Medical Journal

基　　金：南京医科大学科技发展基金重点项目(08NMUZ038)

摘　　要：目的观察唑来磷酸对绝经后乳腺癌患者应用阿那曲唑内分泌治疗导致骨量减少的影响。方法绝经后雌激素受体阳性乳腺癌患者53例,在应用钙剂联合维生素D3制剂基础上分别采用唑来磷酸联合阿那曲唑(治疗组,23例)和阿那曲唑(对照组,30例)治疗。用药方法:唑来磷酸4mg/28d静脉滴注,阿那曲唑1mg/d口服。观察治疗前和治疗6、12、18个月骨密度(BMD)变化。结果与治疗前比较,治疗期治疗组BMD明显升高(P<0.05),而对照组BMD无明显变化(P>0.05)。结论加用唑来磷酸治疗能明显防止绝经后乳腺癌患者阿那曲唑引起的骨量减少作用。Objective To investigate the influence of zoledronic acid on anastrozole-induced osteopenia in postmenopausal women with breast cancer. Methods On the basis of routine calcium plus vitamin D3 treatment, 53 patients with postmenopausal estrogen receptor-positive breast cancer were treated with ananstrozle and zoledronic acid（group A, 23 cases） and with ananstrozle（group B, 30 cases）. Zoledronic acid 4 mg was infused onece every 4 weeks and oral ananstrozle 1 mg/d was used. The changes in bone mineral density（BMD） of lumbar spine and hip bone were followed up in the 6th, 12th and 18th month during treatment. Results Compared to before, BMD was higher during treatment in group A （P^0. 05 ）, which was not significantly changed in group B （P〉0. 05 ）. Conclusion Adding zoledronic acid therapy can effectively prevent anastrozole-induced osteopenia in postmenopausal women with breast cancer.

关 键 词：唑来磷酸 骨密度 阿那曲唑 乳腺癌 

分 类 号：R737[医药卫生—肿瘤]